<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="phts" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">phts</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">PTEN</italic> Hamartoma Tumor Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonym: PHTS</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eng</surname>
            <given-names>Charis</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Genomic Medicine Institute<break/>Cleveland Clinic<break/>Department of Genetics &#x00026; Genome Sciences<break/>Case Western Reserve University School of Medicine<break/>Cleveland, Ohio</aff>
          <email>engc@ccf.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2001-11-29" date-type="created">
          <day>29</day>
          <month>11</month>
          <year>2001</year>
        </date>
        <date iso-8601-date="2016-06-02" date-type="updated">
          <day>2</day>
          <month>6</month>
          <year>2016</year>
        </date>
        <date iso-8601-date="2012-04-19" date-type="revised">
          <day>19</day>
          <month>4</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="prss1-hp" document-type="chapter">
<italic toggle="yes">PRSS1</italic>-Related Hereditary Pancreatitis</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="pura-dis" document-type="chapter"><italic toggle="yes">PURA</italic>-Related Neurodevelopmental Disorders</related-object>
      <abstract id="phts.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>The <italic toggle="yes">PTEN</italic> hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), <italic toggle="yes">PTEN</italic>-related Proteus syndrome (PS), and Proteus-like syndrome.</p>
          <list list-type="bullet">
            <list-item>
              <p>CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The risk for endometrial cancer may approach 28%.</p>
            </list-item>
            <list-item>
              <p>BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis.</p>
            </list-item>
            <list-item>
              <p>PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses.</p>
            </list-item>
            <list-item>
              <p>Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of PHTS is established in a proband by identification of a heterozygous germline <italic toggle="yes">PTEN</italic> pathogenic variant on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment for the benign and malignant manifestations of PHTS is the same as for their sporadic counterparts. Topical agents (e.g., 5-fluorouracil), curettage, cryosurgery, or laser ablation may alleviate the mucocutaneous manifestations of CS but are rarely utilized; cutaneous lesions should be excised only if malignancy is suspected or symptoms (e.g., pain, deformity, increased scarring) are significant.</p>
          <p><italic toggle="yes">Surveillance:</italic> To detect tumors at the earliest, most treatable stages:</p>
          <list list-type="bullet">
            <list-item>
              <p>Children (age &#x0003c;18 years). Yearly thyroid ultrasound from the time of diagnosis and skin check with physical examination.</p>
            </list-item>
            <list-item>
              <p>Adults. Yearly thyroid ultrasound and dermatologic evaluation.</p>
            </list-item>
            <list-item>
              <p>Women beginning at age 30 years. Monthly breast self-examination; annual breast screening (at minimum mammogram; MRI may also be incorporated) and transvaginal ultrasound or endometrial biopsy.</p>
            </list-item>
            <list-item>
              <p>Men and women. Colonoscopy beginning at age 35 years with frequency dependent on degree of polyposis identified; biennial (every 2 years) renal imaging (CT or MRI preferred) beginning at age 40 years.</p>
            </list-item>
            <list-item>
              <p>Those with a family history of a particular cancer type at an early age. Consider initiating screening 5-10 years prior to the youngest age of diagnosis in the family.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> When a <italic toggle="yes">PTEN</italic> pathogenic variant has been identified in a proband, molecular genetic testing of asymptomatic at-risk relatives can identify those who have the family-specific pathogenic variant and warrant ongoing surveillance.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>PHTS is inherited in an autosomal dominant manner. Because CS is likely underdiagnosed, the actual proportion of simplex cases (defined as individuals with no obvious family history) and familial cases (defined as &#x02265;2 related affected individuals) cannot be determined. The majority of CS cases are simplex. Perhaps 10%-50% of individuals with CS have an affected parent. Each child of an affected individual has a 50% chance of inheriting the pathogenic variant and developing PHTS. Once a <italic toggle="yes">PTEN</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk is a possible option.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="phts.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="phts.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_phts.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">PTEN</italic> Hamartoma Tumor Syndrome: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_phts.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Cowden syndrome (CS)</p>
                    </list-item>
                    <list-item>
                      <p>Bannayan-Riley-Ruvalcaba syndrome (BRRS)</p>
                    </list-item>
                    <list-item>
                      <p><italic toggle="yes">PTEN</italic>-related Proteus syndrome</p>
                    </list-item>
                    <list-item>
                      <p>Proteus-like syndrome</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="phts.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="phts.Diagnosis">
        <title>Diagnosis</title>
        <sec id="phts.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>The <italic toggle="yes">PTEN</italic> hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), <italic toggle="yes">PTEN</italic>-related Proteus syndrome (PS), and Proteus-like syndrome.</p>
          <p>A <italic toggle="yes">PTEN</italic> hamartoma tumor syndrome (PHTS) <bold>should be suspected</bold> in individuals with the following clinical features:</p>
          <p><bold>Cowden syndrome (CS).</bold> Based on more than 3000 prospectively accrued individuals with CS or a Cowden-like syndrome (CSL) from the community, a scoring system (which can be found <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.lerner.ccf.org/gmi/ccscore/">online</ext-link>) that takes into account phenotype and age at diagnosis has been developed. The scoring system allows input of clinical information on an individual suspected of having CS/CSL and subsequently generates the prior probability of finding a <italic toggle="yes">PTEN</italic> pathogenic variant.</p>
          <list list-type="bullet">
            <list-item>
              <p>In adults, a clinical threshold score of &#x02265;10 leads to a recommendation for referral to a genetics professional to consider PHTS.</p>
            </list-item>
            <list-item>
              <p>In children, macrocephaly and &#x02265;1 of the following leads to the consideration of PHTS:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Autism or developmental delay</p>
                </list-item>
                <list-item>
                  <p>Dermatologic features, including lipomas, trichilemmomas, oral papillomas, or penile freckling</p>
                </list-item>
                <list-item>
                  <p>Vascular features, such as arteriovenous malformations or hemangiomas</p>
                </list-item>
                <list-item>
                  <p>Gastrointestinal polyps</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Additionally, consensus diagnostic criteria for CS have been developed [<xref ref-type="bibr" rid="phts.REF.eng.2000">Eng 2000</xref>] and are updated each year by the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nccn.org/">National Comprehensive Cancer Network</ext-link> [<xref ref-type="bibr" rid="phts.REF3">NCCN 2015</xref>] (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/f_guidelines.asp">full text</ext-link>; registration required). However, the CS scoring system discussed in this section has been shown to be more accurate than the NCCN diagnostic criteria [<xref ref-type="bibr" rid="phts.REF.tan.2011.42">Tan et al 2011</xref>].</p>
          <p>The NCCN consensus clinical diagnostic criteria have been divided into three categories: pathognomonic, major, and minor.</p>
          <p>
            <bold>Pathognomonic criteria</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Adult Lhermitte-Duclos disease (LDD), defined as the presence of a cerebellar dysplastic gangliocytoma [<xref ref-type="bibr" rid="phts.REF.zhou.2003a.1191">Zhou et al 2003a</xref>]</p>
            </list-item>
            <list-item>
              <p>Mucocutaneous lesions:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Trichilemmomas (facial) (see <xref ref-type="fig" rid="phts.F1">Figure 1</xref>)</p>
                </list-item>
                <list-item>
                  <p>Acral keratoses</p>
                </list-item>
                <list-item>
                  <p>Papillomatous lesions (see <xref ref-type="fig" rid="phts.F2">Figure 2</xref>)</p>
                </list-item>
                <list-item>
                  <p>Mucosal lesions</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Major criteria</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Breast cancer</p>
            </list-item>
            <list-item>
              <p>Epithelial thyroid cancer (non-medullary), especially follicular thyroid cancer</p>
            </list-item>
            <list-item>
              <p>Macrocephaly (occipital frontal circumference &#x02265;97th percentile)</p>
            </list-item>
            <list-item>
              <p>Endometrial carcinoma</p>
            </list-item>
          </list>
          <p>
            <bold>Minor criteria</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Other thyroid lesions (e.g., adenoma, multinodular goiter)</p>
            </list-item>
            <list-item>
              <p>Intellectual disability (IQ &#x02264;75)</p>
            </list-item>
            <list-item>
              <p>Hamartomatous intestinal polyps</p>
            </list-item>
            <list-item>
              <p>Fibrocystic disease of the breast</p>
            </list-item>
            <list-item>
              <p>Lipomas</p>
            </list-item>
            <list-item>
              <p>Fibromas</p>
            </list-item>
            <list-item>
              <p>Genitourinary tumors (especially renal cell carcinoma)</p>
            </list-item>
            <list-item>
              <p>Genitourinary malformation</p>
            </list-item>
            <list-item>
              <p>Uterine fibroids</p>
            </list-item>
          </list>
          <p><bold>An operational diagnosis of CS</bold> is made if an individual meets <bold>any one</bold> of the following criteria:</p>
          <list list-type="bullet">
            <list-item>
              <p>Pathognomonic mucocutaneous lesions combined with one of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Six or more facial papules, of which three or more must be trichilemmoma</p>
                </list-item>
                <list-item>
                  <p>Cutaneous facial papules and oral mucosal papillomatosis</p>
                </list-item>
                <list-item>
                  <p>Oral mucosal papillomatosis and acral keratoses</p>
                </list-item>
                <list-item>
                  <p>Six or more palmoplantar keratoses</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Two or more major criteria</p>
            </list-item>
            <list-item>
              <p>One major and three or more minor criteria</p>
            </list-item>
            <list-item>
              <p>Four or more minor criteria</p>
            </list-item>
          </list>
          <p>In a family in which one individual meets the diagnostic criteria for CS listed above, other relatives are considered to have a diagnosis of CS if they meet <bold>any one</bold> of the following criteria:</p>
          <list list-type="bullet">
            <list-item>
              <p>The pathognomonic criteria</p>
            </list-item>
            <list-item>
              <p>Any one major criterion with or without minor criteria</p>
            </list-item>
            <list-item>
              <p>Two minor criteria</p>
            </list-item>
            <list-item>
              <p>History of Bannayan-Riley-Ruvalcaba syndrome</p>
            </list-item>
          </list>
          <p><bold>Bannayan-Riley-Ruvalcaba syndrome (BRRS).</bold> Diagnostic criteria for BRRS have not been set but are based heavily on the presence of the cardinal features of macrocephaly, hamartomatous intestinal polyposis, lipomas, and pigmented macules of the glans penis [<xref ref-type="bibr" rid="phts.REF.gorlin.1992.307">Gorlin et al 1992</xref>].</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="proteus" document-type="chapter"><bold>Proteus syndrome</bold></related-object>
<bold>(PS)</bold> is highly variable and appears to affect individuals in a mosaic distribution (i.e., only some organs/tissues are affected). Thus, it is frequently misdiagnosed despite the development of consensus diagnostic criteria [<xref ref-type="bibr" rid="phts.REF.biesecker.1999.389">Biesecker et al 1999</xref>] (see <related-object link-type="booklink" source-id="gene" document-id="proteus" document-type="chapter">Proteus Syndrome</related-object>).</p>
          <p><bold>Proteus-like syndrome</bold> is undefined but describes individuals with significant clinical features of PS but who do not meet the diagnostic criteria.</p>
        </sec>
        <sec id="phts.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of PHTS <bold>is established</bold> in a proband by identification of a heterozygous germline pathogenic variant in <italic toggle="yes">PTEN</italic> on molecular genetic testing (see <xref ref-type="table" rid="phts.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">PTEN</italic> is performed first, followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found. If a pathogenic variant is not identified with deletion/duplication analysis, perform sequence analysis of the <italic toggle="yes">PTEN</italic> promoter region for variants that decrease gene expression.Note: In individuals with Cowden syndrome (CS) and Cowden-like syndrome also consider <italic toggle="yes">KLLN</italic> promoter methylation analysis (see Differential Diagnosis, <xref ref-type="sec" rid="phts.Germline_KLLN_Epimutation">Germline <italic toggle="yes">KLLN</italic> Epimutation</xref>), <italic toggle="yes">SDHB-D</italic> analysis (see Differential Diagnosis, <xref ref-type="sec" rid="phts.New_Susceptibility_Genes_in_Individ">New Susceptibility Genes in Individuals with Non-PHTS CS and a CS-Like Disorder</xref>) including <italic toggle="yes">PIK3CA, AKT1</italic> [<xref ref-type="bibr" rid="phts.REF.orloff.2013.76">Orloff et al 2013</xref>], and <italic toggle="yes">SEC23B</italic> [<xref ref-type="bibr" rid="phts.REF.yehia.2015.661">Yehia et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">PTEN</italic> and other genes of interest (see <xref ref-type="sec" rid="phts.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including whole-exome sequencing (WES) or whole-genome sequencing (WGS) may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes <italic toggle="yes">PTEN</italic>) fails to confirm a diagnosis in an individual with features of PHTS. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="phts.T.molecular_genetic_testing_used_in" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">PTEN</italic> Hamartoma Tumor Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_2">Test Method</th>
                  <th id="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" colspan="4" align="left" scope="colgroup" rowspan="1">Proportion of Probands by Phenotype with a Pathogenic Variant Detectable by This Method<hr/></th>
                </tr>
                <tr>
                  <th headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">CS</th>
                  <th headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">BRRS</th>
                  <th headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PLS</th>
                  <th headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PS</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">PTEN</italic>
                  </td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis of coding region&#x000a0;<sup>2</sup><hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">25%-80%<hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">60%<hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">50%&#x000a0;<sup>3</sup><hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">20%<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup><hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">See footnote 5<hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">11%&#x000a0;<sup>6</sup><hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown<hr/></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of promoter region&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">10%&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">See footnote 5</td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  <td headers="hd_h_phts.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_phts.T.molecular_genetic_testing_used_in_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>CS = Cowden syndrome</p>
              </fn>
              <fn>
                <p>BRRS = Bannayan-Riley-Ruvalcaba syndrome</p>
              </fn>
              <fn>
                <p>PLS = Proteus-like syndrome</p>
              </fn>
              <fn>
                <p>PS = <italic toggle="yes">PTEN</italic>-related Proteus syndrome</p>
              </fn>
              <fn id="phts.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="phts" object-id="phts.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="phts.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="phts.TF.1.2">
                <label>2. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="phts.TF.1.3">
                <label>3. </label>
                <p>Data suggest that up to 50% of individuals with a Proteus-like syndrome and 20% of individuals who meet the clinical diagnostic criteria of Proteus syndrome have <italic toggle="yes">PTEN</italic> pathogenic variants [<xref ref-type="bibr" rid="phts.REF.zhou.2001.210">Zhou et al 2001</xref>, <xref ref-type="bibr" rid="phts.REF.smith.2002.937">Smith et al 2002</xref>, <xref ref-type="bibr" rid="phts.REF.eng.2003.183">Eng 2003</xref>, <xref ref-type="bibr" rid="phts.REF.loffeld.2006.1194">Loffeld et al 2006</xref>, <xref ref-type="bibr" rid="phts.REF.orloff.2008.5387">Orloff &#x00026; Eng 2008</xref>].</p>
              </fn>
              <fn id="phts.TF.1.4">
                <label>4. </label>
                <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="phts.TF.1.5">
                <label>5. </label>
                <p>Finite but unknown; individuals with CS who have large deletions have been reported [<xref ref-type="bibr" rid="phts.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>, <xref ref-type="bibr" rid="phts.REF.orloff.2008.5387">Orloff &#x00026; Eng 2008</xref>, <xref ref-type="bibr" rid="phts.REF.tan.2011.42">Tan et al 2011</xref>].</p>
              </fn>
              <fn id="phts.TF.1.6">
                <label>6. </label>
                <p>Approximately 10% of individuals with BRRS who do not have a pathogenic variant detected in the <italic toggle="yes">PTEN</italic> coding sequence have large deletions within or encompassing <italic toggle="yes">PTEN</italic> [<xref ref-type="bibr" rid="phts.REF.zhou.2003b.404">Zhou et al 2003b</xref>].</p>
              </fn>
              <fn id="phts.TF.1.7">
                <label>7. </label>
                <p>10% of individuals with CS phenotype do not have an identifiable <italic toggle="yes">PTEN</italic> sequence variant in the coding/flanking intronic regions [<xref ref-type="bibr" rid="phts.REF.zhou.2003b.404">Zhou et al 2003b</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="phts.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="phts.Clinical_Description">
          <title>Clinical Description</title>
          <p>The <italic toggle="yes">PTEN</italic> hamartoma tumor syndrome (PHTS) is characterized by hamartomatous tumors and germline <italic toggle="yes">PTEN</italic> pathogenic variants. Clinically, PHTS includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), <italic toggle="yes">PTEN</italic>-related Proteus syndrome (PS), and Proteus-like syndrome.</p>
          <list list-type="bullet">
            <list-item>
              <p>CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, and endometrium. Renal cell carcinoma and colorectal carcinoma have recently been shown to be in the PHTS spectrum.</p>
            </list-item>
            <list-item>
              <p>BRRS is a congenital disorder characterized by macrocephaly, intestinal polyposis, lipomas, and pigmented macules of the glans penis.</p>
            </list-item>
            <list-item>
              <p>PS is a complex, highly variable disorder involving congenital malformations and overgrowth of multiple tissues.</p>
            </list-item>
            <list-item>
              <p>Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</p>
            </list-item>
          </list>
          <p><bold>Cowden syndrome (CS).</bold> More than 90% of individuals with CS have some clinical manifestation of the disorder by the late 20s [<xref ref-type="bibr" rid="phts.REF.nelen.1996.114">Nelen et al 1996</xref>, <xref ref-type="bibr" rid="phts.REF.eng.2000">Eng 2000</xref>]. By the third decade, 99% of affected individuals develop the mucocutaneous stigmata (primarily trichilemmomas and papillomatous papules) as well as acral and plantar keratoses. In addition, individuals with Cowden syndrome usually have macrocephaly and dolicocephaly.</p>
          <p>Hamartomatous and mixed gastrointestinal polyps, seen frequently in the majority of people with PHTS, do confer an increased risk for colorectal cancers [<xref ref-type="bibr" rid="phts.REF.heald.2010.1927">Heald et al 2010</xref>].</p>
          <p>Based on anecdotal observations, glycogenic acanthosis in the presence of features of CS appears to be associated with a high likelihood of finding a <italic toggle="yes">PTEN</italic> pathogenic variant [<xref ref-type="bibr" rid="phts.REF.eng.2003.183">Eng 2003</xref>, <xref ref-type="bibr" rid="phts.REF.mcgarrity.2003.1429">McGarrity et al 2003</xref>].</p>
          <p><bold>Tumor risk.</bold> Individuals with CS are at high risk for breast, thyroid, and endometrial cancers. As with other hereditary cancer syndromes, the risk for multifocal and bilateral (in paired organs such as the breasts) cancer is increased:</p>
          <list list-type="bullet">
            <list-item>
              <p>Breast disease</p>
              <list list-type="bullet">
                <list-item>
                  <p>Women with Cowden syndrome are at as high as a 67% risk for benign breast disease.</p>
                </list-item>
                <list-item>
                  <p>An analysis of prospectively accrued and followed probands and family members with a <italic toggle="yes">PTEN</italic> pathogenic variant revealed an 85% lifetime risk for female breast cancer, with 50% penetrance by age 50 years [<xref ref-type="bibr" rid="phts.REF.tan.2012.400">Tan et al 2012</xref>].</p>
                </list-item>
                <list-item>
                  <p>Although breast cancer has been described in males with a <italic toggle="yes">PTEN</italic> pathogenic variant [<xref ref-type="bibr" rid="phts.REF.fackenthal.2001.159">Fackenthal et al 2001</xref>], it was not observed in a study of more than 3000 probands [<xref ref-type="bibr" rid="phts.REF.tan.2011.42">Tan et al 2011</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Thyroid disease</p>
              <list list-type="bullet">
                <list-item>
                  <p>Benign multinodular goiter of the thyroid as well as adenomatous nodules and follicular adenomas are common, occurring in up to 75% of individuals with CS [<xref ref-type="bibr" rid="phts.REF.harach.1999.331">Harach et al 1999</xref>].</p>
                </list-item>
                <list-item>
                  <p>The lifetime risk for epithelial thyroid cancer is approximately 35% [<xref ref-type="bibr" rid="phts.REF.tan.2012.400">Tan et al 2012</xref>]. Median age of onset was 37 years; seven years was the youngest age at diagnosis [<xref ref-type="bibr" rid="phts.REF.ngeow.2011.e2063">Ngeow et al 2011</xref>]. Note: (1) Follicular histology is over-represented in adults compared to the general population in which papillary histology is over-represented. (2) No medullary thyroid carcinoma was observed in the cohort with molecularly confirmed CS.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Endometrial disease</p>
              <list list-type="bullet">
                <list-item>
                  <p>Benign uterine fibroids are common.</p>
                </list-item>
                <list-item>
                  <p>Lifetime risk for endometrial cancer is estimated at 28%, with the starting age at risk in the late 30s to early 40s [<xref ref-type="bibr" rid="phts.REF.tan.2012.400">Tan et al 2012</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Gastrointestinal neoplasias</p>
              <list list-type="bullet">
                <list-item>
                  <p>More than 90% of individuals with a <italic toggle="yes">PTEN</italic> pathogenic variant who underwent at least one upper or lower endoscopy were found to have polyps [<xref ref-type="bibr" rid="phts.REF.heald.2010.1927">Heald et al 2010</xref>]. Histologic findings varied, ranging from ganglioneuromatous polyps, hamartomatous polyps, and juvenile polyps to adenomatous polyps.</p>
                </list-item>
                <list-item>
                  <p>Lifetime risk for colorectal cancer is estimated at 9%, with the starting age at risk in the late 30s [<xref ref-type="bibr" rid="phts.REF.tan.2012.400">Tan et al 2012</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Renal cell carcinoma</p>
              <list list-type="bullet">
                <list-item>
                  <p>Lifetime risk for renal cell carcinoma is estimated at 35%, with the starting age at risk in the 40s [<xref ref-type="bibr" rid="phts.REF.tan.2012.400">Tan et al 2012</xref>]. The predominant histology is papillary renal cell carcinoma [<xref ref-type="bibr" rid="phts.REF.mester.2012.1187.e1">Mester et al 2012</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Other</p>
              <list list-type="bullet">
                <list-item>
                  <p>Lifetime risk for cutaneous melanoma is estimated at more than 5%.</p>
                </list-item>
                <list-item>
                  <p>Brain tumors as well as vascular malformations affecting any organ are occasionally seen in individuals with CS. Note: Because meningioma is so common in the general population, it is not yet clear if meningioma is a true manifestation of CS.</p>
                </list-item>
                <list-item>
                  <p>A rare central nervous system tumor, cerebellar dysplastic gangliocytoma (Lhermitte-Duclos disease) is also found in CS and may be pathognomonic.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Bannayan-Riley-Ruvalcaba syndrome (BRRS).</bold> Common features of BRRS, in addition to those mentioned <xref ref-type="sec" rid="phts.Clinical_Description">above</xref>, include high birth weight, developmental delay, and intellectual disability (50% of affected individuals), a myopathic process in proximal muscles (60%), joint hyperextensibility, pectus excavatum, and scoliosis (50%) [<xref ref-type="bibr" rid="phts.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>].</p>
          <p>Individuals with BRRS and a <italic toggle="yes">PTEN</italic> pathogenic variant are thought to have the same cancer risks as individuals with CS. Note: It is not clear whether these risks apply to individuals with BRRS who do not have a <italic toggle="yes">PTEN</italic> pathogenic variant.</p>
          <p>The gastrointestinal hamartomatous polyps in BRRS (seen in 45% of affected individuals) may occasionally be associated with intussusception, but rectal bleeding and oozing of "serum" is more common. These polyps are not believed to increase the risk for colorectal cancer. PHTS hamartomatous polyps are different in histomorphology from the polyps seen in <related-object link-type="booklink" source-id="gene" document-id="pjs" document-type="chapter">Peutz-Jeghers syndrome</related-object>.</p>
          <p><bold><italic toggle="yes">PTEN</italic>-related Proteus syndrome (PS)</bold> is characterized by progressive segmental or patchy overgrowth of diverse tissues of all germ layers, most commonly affecting the skeleton, skin, and adipose and central nervous systems. In most individuals Proteus syndrome has minimal or no manifestations at birth, develops and progresses rapidly beginning in the toddler period, and relentlessly progresses through childhood, causing severe overgrowth and disfigurement. It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism. See <related-object link-type="booklink" source-id="gene" document-id="proteus" document-type="chapter">Proteus Syndrome</related-object>.</p>
          <p><bold>Proteus-like syndrome</bold> is undefined but describes individuals with significant clinical features of PS who do not meet the diagnostic criteria.</p>
        </sec>
        <sec id="phts.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>For purposes of <italic toggle="yes">PTEN</italic> genotype-phenotype analyses, a series of 37 unrelated probands with CS were ascertained by the operational diagnostic criteria of the International Cowden Consortium, 1995 version [<xref ref-type="bibr" rid="phts.REF.nelen.1996.114">Nelen et al 1996</xref>, <xref ref-type="bibr" rid="phts.REF.eng.2000">Eng 2000</xref>]. Association analyses revealed that families with CS and a germline <italic toggle="yes">PTEN</italic> pathogenic variant are more likely to develop malignant breast disease than are families who do not have a <italic toggle="yes">PTEN</italic> pathogenic variant [<xref ref-type="bibr" rid="phts.REF.marsh.1998.507">Marsh et al 1998</xref>]. In addition, pathogenic missense variants and others 5' to or within the phosphatase core motif appeared to be associated with involvement of five or more organs, a surrogate phenotype for severity of disease [<xref ref-type="bibr" rid="phts.REF.marsh.1998.507">Marsh et al 1998</xref>].</p>
          <p>More than 90% of families with CS-BRRS overlap were found to have a germline <italic toggle="yes">PTEN</italic> pathogenic variant. The mutational spectra of BRRS and CS have been shown to overlap, thus lending formal proof that CS and BRRS are allelic [<xref ref-type="bibr" rid="phts.REF.marsh.1999.1461">Marsh et al 1999</xref>]. No difference in mutation frequencies was observed between BRRS occurring in a single individual in a family and BRRS occurring in multiple family members.</p>
          <p>An individual presenting as a simplex case (i.e., one with no known family history) of Proteus-like syndrome comprising hemihypertrophy, macrocephaly, lipomas, connective tissue nevi, and multiple arteriovenous malformations was found to have a germline p.Arg335Ter <italic toggle="yes">PTEN</italic> pathogenic variant and the same somatic pathogenic variant (p.Arg130Ter) in three separate tissues, possibly representing germline mosaicism [<xref ref-type="bibr" rid="phts.REF.zhou.2000.765">Zhou et al 2000</xref>]. Both pathogenic variants have been previously described in classic CS and BRRS.</p>
          <p>Two of nine individuals who met the clinical diagnostic criteria of Proteus syndrome and three of six with Proteus-like syndrome were found to have germline <italic toggle="yes">PTEN</italic> pathogenic variants [<xref ref-type="bibr" rid="phts.REF.zhou.2001.210">Zhou et al 2001</xref>]. Since then multiple single cases of germline <italic toggle="yes">PTEN</italic> pathogenic variants in individuals who met the clinical diagnostic criteria of Proteus and Proteus-like syndrome have been reported [<xref ref-type="bibr" rid="phts.REF.smith.2002.937">Smith et al 2002</xref>, <xref ref-type="bibr" rid="phts.REF.loffeld.2006.1194">Loffeld et al 2006</xref>].</p>
        </sec>
        <sec id="phts.Penetrance">
          <title>Penetrance</title>
          <p>More than 90% of individuals with CS have some clinical manifestation of the disorder by the late 20s [<xref ref-type="bibr" rid="phts.REF.nelen.1996.114">Nelen et al 1996</xref>, <xref ref-type="bibr" rid="phts.REF.eng.2000">Eng 2000</xref>, <xref ref-type="bibr" rid="phts.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>]. By the third decade, 99% of affected individuals develop the mucocutaneous stigmata, primarily trichilemmomas and papillomatous papules, as well as acral and plantar keratoses. (See also <xref ref-type="sec" rid="phts.Clinical_Description">Clinical Description</xref> for age at which specific manifestations are likely to become evident.)</p>
        </sec>
        <sec id="phts.Nomenclature">
          <title>Nomenclature</title>
          <p>Cowden syndrome, Cowden disease, and multiple hamartoma syndrome have been used interchangeably.</p>
          <p>Bannayan-Riley-Ruvalcaba syndrome, Bannayan-Ruvalcaba-Riley syndrome, Bannayan-Zonana syndrome, and Myhre-Riley-Smith syndrome refer to a similar constellation of signs that comprise what the authors refer to as BRRS. When a <italic toggle="yes">PTEN</italic> pathogenic variant is found, the gene-related name, PHTS, should be used.</p>
          <p>One form of Proteus-like syndrome, with a clinical presentation similar to that first described by <xref ref-type="bibr" rid="phts.REF.zhou.2000.765">Zhou et al [2000]</xref> and with a germline <italic toggle="yes">PTEN</italic> pathogenic variant, was termed SOLAMEN (<italic toggle="yes">s</italic>egmental <italic toggle="yes">o</italic>vergrowth, <italic toggle="yes">l</italic>ipomatosis, <italic toggle="yes">a</italic>rteriovenous <italic toggle="yes">m</italic>alformation and <italic toggle="yes">e</italic>pidermal <italic toggle="yes">n</italic>evus) syndrome [<xref ref-type="bibr" rid="phts.REF.caux.2007.767">Caux et al 2007</xref>]. This is not useful, especially in the molecular era, as any phenotype associated with a <italic toggle="yes">PTEN</italic> pathogenic variant should be termed PHTS with all its implications for clinical management [<xref ref-type="bibr" rid="phts.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>, <xref ref-type="bibr" rid="phts.REF.orloff.2008.5387">Orloff &#x00026; Eng 2008</xref>].</p>
        </sec>
        <sec id="phts.Prevalence">
          <title>Prevalence</title>
          <p>Because the diagnosis of CS is difficult to establish, the true prevalence is unknown. The prevalence has been estimated at one in 200,000 [<xref ref-type="bibr" rid="phts.REF.nelen.1999.267">Nelen et al 1999</xref>], likely an underestimate. Because of the variable and often subtle external manifestations of CS/BRRS, many individuals remain undiagnosed [<xref ref-type="bibr" rid="phts.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>; Eng, unpublished].</p>
        </sec>
      </sec>
      <sec id="phts.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, <italic toggle="yes">PTEN</italic>-related Proteus syndrome, and Proteus-like syndrome are known to be <bold>consistently</bold> caused by pathogenic variants in <italic toggle="yes">PTEN</italic>.</p>
        <p>Phenotypes that can be associated with <italic toggle="yes">PTEN</italic> germline pathogenic variants:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lhermitte-Duclos disease (LDD).</bold> Most, if not all, adult-onset Lhermitte-Duclos disease (dysplastic gangliocytoma of the cerebellum, a hamartomatous overgrowth known to be a feature of CS) can be attributed to pathogenic variants in <italic toggle="yes">PTEN</italic>, even in the absence of other clinical signs of CS/BRRS. However, germline <italic toggle="yes">PTEN</italic> pathogenic variants appear to be rare in individuals with childhood-onset LDD [<xref ref-type="bibr" rid="phts.REF.zhou.2003a.1191">Zhou et al 2003a</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Autism/pervasive developmental disorder and macrocephaly.</bold> Germline <italic toggle="yes">PTEN</italic> pathogenic variants were identified in individuals with these findings, especially in the presence of other personal or family history consistent with CS/BRRS [<xref ref-type="bibr" rid="phts.REF.dasouki.2001.s280">Dasouki et al 2001</xref>, <xref ref-type="bibr" rid="phts.REF.goffin.2001.521">Goffin et al 2001</xref>]. <xref ref-type="bibr" rid="phts.REF.butler.2005.318">Butler et al [2005]</xref> found that approximately 20% of individuals with autism spectrum disorders and macrocephaly have germline <italic toggle="yes">PTEN</italic> pathogenic variants. The 10%-20% prevalence of germline <italic toggle="yes">PTEN</italic> pathogenic variants in autism spectrum disorders with macrocephaly has now been confirmed by several independent groups [<xref ref-type="bibr" rid="phts.REF.herman.2007a.589">Herman et al 2007a</xref>, <xref ref-type="bibr" rid="phts.REF.herman.2007b.268">Herman et al 2007b</xref>, <xref ref-type="bibr" rid="phts.REF.orrico.2009.195">Orrico et al 2009</xref>, <xref ref-type="bibr" rid="phts.REF.varga.2009.111">Varga et al 2009</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Juvenile polyposis of infancy (JPI).</bold> In this rare condition, caused by germline deletion of <italic toggle="yes">BMPR1A</italic> and <italic toggle="yes">PTEN,</italic> juvenile polyposis is diagnosed before age six years [<xref ref-type="bibr" rid="phts.REF.delnatte.2006.1066">Delnatte et al 2006</xref>]. Often the gastrointestinal manifestations of bleeding, diarrhea, and protein-losing enteropathy are severe. External stigmata may mimic BRRS.</p>
          </list-item>
        </list>
      </sec>
      <sec id="phts.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <table-wrap id="phts.T.disorders_to_consider_in_the_diff" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Disorders to Consider in the Differential Diagnosis of <italic toggle="yes">PTEN</italic> Hamartoma Tumor Syndrome</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1">Disorder</th>
                <th id="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2">Gene(s)</th>
                <th id="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3">MOI</th>
                <th id="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Clinical Features<hr/></th>
              </tr>
              <tr>
                <th headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Overlapping</th>
                <th headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">General</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" colspan="5" align="left" scope="col" rowspan="1">
                  <bold>Primary differential diagnoses to consider: other hamartoma syndromes incl JPS &#x00026; PJS</bold>
                  <hr/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="jps" document-type="chapter">JPS</related-object>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">BMPR1A<break/>SMAD4</italic>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Hamartomatous gastrointestinal polyps&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">JPS is characterized by predisposition to hamartomatous polyps in the GI tract.<break/>Most individuals w/JPS have some polyps by age 20 years; some may have only 4-5 polyps over their lifetime; others in the same family may have &#x0003e;100.<break/>Left untreated, polyps may cause bleeding &#x00026; anemia. Most juvenile polyps are benign; however, malignant transformation can occur.<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="pjs" document-type="chapter">PJS</related-object>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">STK11</italic>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Hamartomatous gastrointestinal polyps&#x000a0;<sup>2</sup><hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">PJS is characterized by GI polyposis, mucocutaneous pigmentation, &#x00026; cancer predisposition.<break/>The pigmentation of the perioral region is pathognomonic, particularly if it crosses the vermilion border. Hyperpigmented macules on the fingers are also common.<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" colspan="5" align="left" scope="col" rowspan="1">
                  <bold>Less likely differential diagnoses to consider</bold>
                  <hr/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="bhd" document-type="chapter">BHD</related-object>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">FLCN<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Cutaneous manifestations incl skin tags, fibromas, &#x00026; trichiepitheliomas (can be mistaken for trichilemmomas)<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">BHD is characterized by cutaneous findings&#x000a0;<sup>3</sup>, pulmonary cysts/history of pneumothorax, &#x00026; various types of renal tumors&#x000a0;<sup>4</sup>.<break/>Lung cysts are mostly bilateral &#x00026; multifocal; most individuals are asymptomatic but at high risk for spontaneous pneumothorax.<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">NF1</related-object>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">NF1</italic>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Caf&#x000e9;-au-lait macules &#x00026; fibromatous tumors of the skin&#x000a0;<sup>5</sup><hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">The diagnosis of NF1 may be mistakenly given to persons w/CS/BRRS due to presence of ganglioneuromas in the GI tract.<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="bcns" document-type="chapter">Nevoid basal cell<break/>carcinoma<break/>(Gorlin) syndrome</related-object>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">PTCH1<break/>SUFU</italic>
                  <hr/>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Hamartomatous gastric polyps<hr/></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Gorlin syndrome is characterized by the development of multiple jaw keratocysts and/or basal cell carcinomas.<break/>Affected individuals can also develop other tumors &#x00026; cancers incl fibromas, hamartomatous gastric polyps, &#x00026; medulloblastomas.<break/>The dermatologic findings &#x00026; developmental features in CS &#x00026; Gorlin syndrome are quite different.<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">AKT1</italic>-related <related-object link-type="booklink" source-id="gene" document-id="proteus" document-type="chapter">Proteus syndrome</related-object></td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">AKT1</italic>
                </td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 6</td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Proteus syndrome is a &#x02018;PTEN-pathway-opathy&#x02019;&#x000a0;<sup>7</sup><break/>Macrocephaly, overgrowth</td>
                <td headers="hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_phts.T.disorders_to_consider_in_the_diff_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Proteus syndrome is characterized by progressive segmental or patchy overgrowth of diverse tissues of all germ layers.<break/>In most individuals: minimal or no manifestations at birth; progresses rapidly beginning in the toddler period and relentlessly through childhood, causing severe overgrowth &#x00026; disfigurement<break/>Associated w/a range of tumors, pulmonary complications, &#x00026; a striking predisposition to deep vein thrombosis &#x00026; pulmonary embolism</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MOI = mode of inheritance</p>
            </fn>
            <fn>
              <p>AD = autosomal dominant</p>
            </fn>
            <fn>
              <p>AR = autosomal recessive</p>
            </fn>
            <fn>
              <p>XL = X-linked</p>
            </fn>
            <fn>
              <p>JPS = juvenile polyposis syndrome; the term "juvenile" refers to the type of polyp rather than to the age of onset of polyps.</p>
            </fn>
            <fn>
              <p>GI = gastrointestinal</p>
            </fn>
            <fn>
              <p>PJS = Peutz-Jeghers syndrome</p>
            </fn>
            <fn>
              <p>BHD = Birt-Hogg-Dub&#x000e9; syndrome</p>
            </fn>
            <fn>
              <p>NF1 = neurofibromatosis type 1</p>
            </fn>
            <fn id="phts.TF.2.1">
              <label>1. </label>
              <p>Juvenile polyps are hamartomas that show a normal epithelium with a dense stroma, an inflammatory infiltrate, and a smooth surface with dilated, mucus-filled cystic glands in the lamina propria. (See <related-object link-type="booklink" source-id="gene" document-id="jps" document-type="chapter">Juvenile Polyposis Syndrome</related-object>.)</p>
            </fn>
            <fn id="phts.TF.2.2">
              <label>2. </label>
              <p>The Peutz-Jeghers polyp has a diagnostic appearance and is quite different from the hamartomatous polyps seen in CS or JPS. Clinically, Peutz-Jeghers polyps are often symptomatic (intussusception, rectal bleeding), whereas CS polyps are rarely so. (See <related-object link-type="booklink" source-id="gene" document-id="pjs" document-type="chapter">Peutz-Jeghers Syndrome</related-object>.)</p>
            </fn>
            <fn id="phts.TF.2.3">
              <label>3. </label>
              <p>Cutaneous findings characteristic of BHD: fibrofolliculomas, trichodiscomas/angiofibromas, perifollicular fibromas, and acrochordons. Skin lesions typically appear during the third or fourth decade of life and usually increase in size and number with age. (See <related-object link-type="booklink" source-id="gene" document-id="bhd" document-type="chapter">Birt-Hogg-Dub&#x000e9; syndrome</related-object>.)</p>
            </fn>
            <fn id="phts.TF.2.4">
              <label>4. </label>
              <p>Individuals with BHDS are at increased risk for renal tumors that are typically bilateral and multifocal, and usually slow growing.</p>
            </fn>
            <fn id="phts.TF.2.5">
              <label>5. </label>
              <p>The only two features seen in both NF1 and CS/BRRS are caf&#x000e9;-au-lait macules and fibromatous tumors of the skin. (See <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">Neurofibromatosis type 1</related-object>.)</p>
            </fn>
            <fn id="phts.TF.2.6">
              <label>6. </label>
              <p>All individuals with clinically confirmed Proteus syndrome (known to authors of the <related-object link-type="booklink" source-id="gene" document-id="proteus" document-type="chapter">Proteus Syndrome</related-object>
<italic toggle="yes">GeneReview</italic>) have been simplex cases caused by somatic mosaicism for the specific <italic toggle="yes">de novo AKT1</italic> pathogenic variant c.49G&#x0003e;A (p.Glu17Lys).</p>
            </fn>
            <fn id="phts.TF.2.7">
              <label>7. </label>
              <p>Since <italic toggle="yes">PTEN</italic> down-regulates <italic toggle="yes">AKT1</italic> by decreasing phosphorylation, the finding of an activating <italic toggle="yes">AKT1</italic> pathogenic variant in Proteus syndrome confirms that Proteus syndrome is a &#x02018;PTEN-pathway-opathy.&#x02019;</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <sec id="phts.Germline_KLLN_Epimutation">
          <title>Germline <italic toggle="yes">KLLN</italic> Epimutation</title>
          <p><xref ref-type="bibr" rid="phts.REF.bennett.2010.2724">Bennett et al [2010]</xref> determined that approximately 30% of individuals with Cowden syndrome (CS) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615107">OMIM</ext-link>) and Cowden-like syndrome who do not have a <italic toggle="yes">PTEN</italic> germline pathogenic variant have a germline <italic toggle="yes">KLLN</italic> methylation epimutation, which resulted in down-regulation of expression of <italic toggle="yes">KLLN</italic>, but not of <italic toggle="yes">PTEN</italic>. Of note, <italic toggle="yes">KLLN</italic> shares a bidirectional promoter with <italic toggle="yes">PTEN</italic>. Pilot data suggest that individuals with CS and Cowden-like syndrome with a germline <italic toggle="yes">KLLN</italic> epimutation have a greater prevalence of breast and renal cell carcinomas than do those with a germline <italic toggle="yes">PTEN</italic> pathogenic variant. Thus, individuals with Cowden-like syndrome (especially those with breast and/or renal carcinomas or a family history of such tumors) should be offered <italic toggle="yes">KLLN</italic> methylation analysis first because it accounts for 30% of such individuals, whereas <italic toggle="yes">PTEN</italic> germline pathogenic variants account for 5%-10%.</p>
        </sec>
        <sec id="phts.New_Susceptibility_Genes_in_Individ">
          <title>New Susceptibility Genes in Individuals with Non-PHTS CS and a CS-Like Disorder</title>
          <p>A pilot study found that individuals with Cowden syndrome (CS) and a CS-like (CSL) disorder without germline <italic toggle="yes">PTEN</italic> pathogenic variants (but with increased levels of manganese superoxide dismutase) harbored germline variants in <italic toggle="yes">SDHB</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612359">OMIM</ext-link>) and <italic toggle="yes">SDHD</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615106">OMIM</ext-link>) [<xref ref-type="bibr" rid="phts.REF.ni.2008.261">Ni et al 2008</xref>]. That germline variants in <italic toggle="yes">SDHB, SDHC,</italic> and <italic toggle="yes">SDHD</italic> occur in approximately 10% of persons with CS or CSL who do not have a <italic toggle="yes">PTEN</italic> pathogenic variant has been validated in an independent series of 608 research participants [<xref ref-type="bibr" rid="phts.REF.ni.2012.300">Ni et al 2012</xref>]. These variants were associated with stabilization of HIF1a, destabilization of p53 secondary to decreased NQ01 interaction, and increased reactive oxygen species with consequent apoptosis resistance. Approximately 10% of individuals with CS/CSL disorder without germline <italic toggle="yes">PTEN</italic> or <italic toggle="yes">SDHx</italic> pathogenic variants have been found to harbor germline <italic toggle="yes">PIK3CA</italic> (see <related-object link-type="booklink" source-id="gene" document-id="pik3ca-overgrowth" document-type="chapter"><italic toggle="yes">PIK3CA</italic>-Related Segmental Overgrowth</related-object>) or <italic toggle="yes">AKT1</italic> pathogenic variants [<xref ref-type="bibr" rid="phts.REF.orloff.2013.76">Orloff et al 2013</xref>]. Another 3%-6% of CS and CS-like individuals without pathogenic variants in the above known genes have germline heterozygous <italic toggle="yes">SEC23B</italic> pathogenic variants, which are particularly associated with thyroid carcinoma [<xref ref-type="bibr" rid="phts.REF.yehia.2015.661">Yehia et al 2015</xref>].</p>
        </sec>
      </sec>
      <sec id="phts.Management">
        <title>Management</title>
        <sec id="phts.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with <italic toggle="yes">PTEN</italic> hamartoma tumor syndrome (PHTS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete medical history and family history</p>
            </list-item>
            <list-item>
              <p>Physical examination with <bold>particular</bold> attention to skin, mucous membranes, thyroid, breasts</p>
            </list-item>
            <list-item>
              <p>In children: consideration of neurodevelopmental evaluation</p>
            </list-item>
            <list-item>
              <p>Urinalysis with cytospin</p>
            </list-item>
            <list-item>
              <p>Baseline thyroid ultrasound examination* (on identification of a <italic toggle="yes">PTEN</italic> pathogenic variant)</p>
            </list-item>
            <list-item>
              <p>For women age &#x02265;30 years at diagnosis*:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Breast screening (at minimum mammogram; MRI may also be incorporated)</p>
                </list-item>
                <list-item>
                  <p>Transvaginal ultrasound or endometrial biopsy</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>For men and women age &#x02265;35 years at diagnosis*: colonoscopy</p>
            </list-item>
            <list-item>
              <p>For men and women age &#x02265;40 years at diagnosis*: renal imaging (CT or MRI preferred)</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
          <p>* For individuals with a family history of a particular cancer type at an early age, screening may be considered five to ten years prior to the youngest diagnosis in the family.</p>
        </sec>
        <sec id="phts.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The mucocutaneous manifestations of Cowden syndrome are rarely life threatening:</p>
          <list list-type="bullet">
            <list-item>
              <p>If asymptomatic, observation alone is prudent.</p>
            </list-item>
            <list-item>
              <p>Cutaneous lesions should be excised only if malignancy is suspected or symptoms (e.g., pain, deformity, increased scarring) are significant.When symptomatic, topical agents (e.g., 5-fluorouracil), curettage, cryosurgery, or laser ablation may provide only temporary relief [<xref ref-type="bibr" rid="phts.REF.hildenbrand.2001.362">Hildenbrand et al 2001</xref>]. Surgical excision is sometimes complicated by cheloid formation and recurrence (often rapid) of the lesions [Eng, unpublished data].</p>
            </list-item>
          </list>
          <p>Treatment for the benign and malignant manifestations of PHTS is the same as for their sporadic counterparts.</p>
        </sec>
        <sec id="phts.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Some women at increased risk for breast cancer consider prophylactic mastectomy, especially if breast tissue is dense or if repeated breast biopsies have been necessary. Prophylactic mastectomy reduces the risk of breast cancer by 90% in women at high risk [<xref ref-type="bibr" rid="phts.REF.hartmann.1999.77">Hartmann et al 1999</xref>]. Note: The recommendation of prophylactic mastectomy is a generalization for women at increased risk for breast cancer from a variety of causes, not just from PHTS.</p>
          <p>No <bold>direct</bold> evidence supports the routine use of agents such as tamoxifen or raloxifene in individuals with PHTS to reduce the risk of developing breast cancer. Physicians should discuss the limitations of the evidence and the risks and benefits of chemoprophylaxis with each individual. In addition, the clinician must discuss the increased risk of endometrial cancer associated with tamoxifen use in a population already at increased risk for endometrial cancer.</p>
        </sec>
        <sec id="phts.Surveillance">
          <title>Surveillance</title>
          <p>The most serious consequences of PHTS relate to the increased risk of cancers including breast, thyroid, endometrial, and to a lesser extent, renal. In this regard, the most important aspect of management of <bold>any</bold> individual with a <italic toggle="yes">PTEN</italic> pathogenic variant is increased cancer surveillance to detect any tumors at the earliest, most treatable stages. Current suggested screening by age follows:</p>
          <sec id="phts.Cowden_Syndrome">
            <title>Cowden Syndrome</title>
            <p>
              <bold>Pediatric (age &#x0003c;18 years)</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Yearly thyroid ultrasound examination** (on identification of a <italic toggle="yes">PTEN</italic> pathogenic variant)</p>
              </list-item>
              <list-item>
                <p>Yearly skin check with physical examination</p>
              </list-item>
            </list>
            <p>
              <bold>Adult</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Yearly thyroid ultrasound** and dermatologic evaluation</p>
              </list-item>
              <list-item>
                <p>Women beginning at age 30 years:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Monthly breast self-examination**</p>
                  </list-item>
                  <list-item>
                    <p>Yearly breast screening (at minimum mammogram); MRI may also be incorporated.**</p>
                  </list-item>
                  <list-item>
                    <p>Yearly transvaginal ultrasound or endometrial biopsy**</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>For men and women:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Colonoscopy beginning at age 35 years**; frequency dependent on degree of polyposis identified</p>
                  </list-item>
                  <list-item>
                    <p>Biennial renal imaging (CT or MRI preferred) beginning at age 40 years**</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p>** For those with a family history of a particular cancer type at an early age screening may be initiated five to ten years prior to the youngest diagnosis in the family. For example, in a woman whose mother developed breast cancer at age 30 years breast surveillance may begin at age 25-30 years.</p>
            <p>Note: Although the NCCN Guidelines removed endometrial surveillance after 2007 (without expert PHTS input), it is prudent to ensure the minimal surveillance for endometrial cancer as detailed if family history is positive for endometrial cancer.</p>
          </sec>
          <sec id="phts.BannayanRileyRuvalcaba_Syndrome">
            <title>Bannayan-Riley-Ruvalcaba Syndrome</title>
            <p>Screening recommendations have not been established for BRRS. Given recent molecular epidemiologic studies, however, individuals with BRRS and a germline <italic toggle="yes">PTEN</italic> pathogenic variant should undergo the same surveillance as individuals with CS.</p>
            <p>Individuals with BRRS should also be monitored for complications related to gastrointestinal hamartomatous polyposis, which can be more severe than in CS.</p>
          </sec>
          <sec id="phts.Proteus_SyndromeProteusLike_Syndrom">
            <title>Proteus Syndrome/Proteus-Like Syndrome</title>
            <p>Although the observation of germline <italic toggle="yes">PTEN</italic> pathogenic variants in a minority of individuals who meet the clinical diagnostic criteria for Proteus syndrome and Proteus-like syndrome is relatively new, clinicians should consider instituting the CS surveillance recommendations for individuals with these disorders who have germline <italic toggle="yes">PTEN</italic> pathogenic variants.</p>
          </sec>
        </sec>
        <sec id="phts.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Because of the propensity for rapid tissue regrowth and the propensity to form keloid tissue, it is recommended that cutaneous lesions be excised only if malignancy is suspected or symptoms (e.g., pain, deformity) are significant.</p>
        </sec>
        <sec id="phts.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>When a <italic toggle="yes">PTEN</italic> pathogenic variant has been identified in a proband, testing of asymptomatic at-risk relatives can identify those who have the family-specific pathogenic variant and, therefore, have PHTS. These individuals are in need of <xref ref-type="sec" rid="phts.Evaluations_Following_Initial_Diagn">initial evaluation</xref> and ongoing <xref ref-type="sec" rid="phts.Surveillance">surveillance</xref>.</p>
          <p>Molecular testing is appropriate for at-risk individuals younger than age 18 years, given the possible early disease presentation in individuals with BRRS and Proteus syndrome. In individuals with PHTS, the earliest documented breast cancer and thyroid cancer are at age 17 years and before age nine years, respectively.</p>
          <p>Relatives who have not inherited the <italic toggle="yes">PTEN</italic> pathogenic variant found in an affected relative do not have PHTS or its associated cancer risks.</p>
          <p>See <xref ref-type="sec" rid="phts.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="phts.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Although mTOR inhibitors show promise for treatment of malignancies in individuals who have a germline <italic toggle="yes">PTEN</italic> pathogenic variant, use should be limited to clinical trials. A clinical trial specifically directed at PHTS recently concluded; results have not been published at the time of this <italic toggle="yes">GeneReview</italic> update.</p>
          <p>An mTOR inhibitor trial will open shortly for pediatric, adolescent, and young adult patients with germline <italic toggle="yes">PTEN</italic> pathogenic variants and autism spectrum disorder.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="phts.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="phts.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">PTEN</italic> hamartoma tumor syndrome (PHTS) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="phts.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Cowden syndrome (CS).</bold> Because CS is likely underdiagnosed, the actual proportion of simplex cases (defined as individuals with no obvious family history) and familial cases (defined as &#x02265;2 related affected individuals) cannot be determined. As a broad estimate, 55%-90% of individuals with CS have an affected parent [<xref ref-type="bibr" rid="phts.REF.marsh.1999.1461">Marsh et al 1999</xref>, <xref ref-type="bibr" rid="phts.REF.mester.2012.1187.e1">Mester et al 2012</xref>]. However, a family history estimate based on practical experience is likely nearer to 50%.</p>
            </list-item>
            <list-item>
              <p><bold>Bannayan-Riley-Ruvalcaba syndrome (BRRS).</bold> The majority of evidence suggests that <italic toggle="yes">PTEN</italic> pathogenic variants occur in both simplex and familial occurrences of BRRS [<xref ref-type="bibr" rid="phts.REF.eng.2003.183">Eng 2003</xref>, <xref ref-type="bibr" rid="phts.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>].</p>
            </list-item>
            <list-item>
              <p><bold><italic toggle="yes">PTEN</italic>-related Proteus syndrome and Proteus-like syndrome.</bold> Virtually all individuals are simplex cases.</p>
            </list-item>
            <list-item>
              <p>If a <italic toggle="yes">PTEN</italic> pathogenic variant is identified in the proband, the parents should be offered molecular genetic testing to determine if one of them has previously unidentified PHTS.</p>
            </list-item>
            <list-item>
              <p>The family history of many individuals diagnosed with PHTS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband has the <italic toggle="yes">PTEN</italic> pathogenic variant, the risk to the sibs of inheriting the variant is 50%.</p>
            </list-item>
            <list-item>
              <p>If it has been shown that neither parent has the <italic toggle="yes">PTEN</italic> pathogenic variant found in the proband, the risk to sibs is probably negligible, as germline mosaicism has rarely been reported in PHTS [<xref ref-type="bibr" rid="phts.REF.pritchard.2013.1004">Pritchard et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>If the genetic status of the parents is unknown but they have no clinical signs of CS/BRRS and are in their thirties, it is unlikely either parent is heterozygous for a <italic toggle="yes">PTEN</italic> pathogenic variant and the risk to sibs is therefore minimal (<xref ref-type="sec" rid="phts.Penetrance">penetrance</xref> of PHTS is close to 99% by the thirties in individuals with a <italic toggle="yes">PTEN</italic> pathogenic variant).</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with PHTS has a 50% chance of inheriting the <italic toggle="yes">PTEN</italic> pathogenic variant and developing PHTS.</p>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents: if a parent has the <italic toggle="yes">PTEN</italic> pathogenic variant, his or her family members are at risk.</p>
        </sec>
        <sec id="phts.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="phts.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Testing of at-risk relatives.</bold> When a pathogenic variant has been identified in a proband, testing of asymptomatic at-risk relatives can identify those who also have the pathogenic variant and have PHTS. These individuals are in need of <xref ref-type="sec" rid="phts.Evaluations_Following_Initial_Diagn">initial evaluation</xref> and ongoing <xref ref-type="sec" rid="phts.Surveillance">surveillance</xref>. Molecular testing is appropriate for at-risk individuals younger than age 18 years, given the possible early disease presentation in individuals with BRRS and Proteus syndrome, and of thyroid cancer in PHTS.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p>
          <p><bold>Genetic cancer risk assessment and counseling.</bold> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without molecular genetic testing, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</ext-link> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="phts.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">PTEN</italic> pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for PHTS are possible options.</p>
        </sec>
      </sec>
      <sec id="phts.Resources">
        <title>Resources</title>
      </sec>
      <sec id="phts.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="phts.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>While much functional research has been accomplished, complete function of PTEN is not yet fully understood. PTEN belongs to a sub-class of phosphatases called dual-specificity phosphatases that remove phosphate groups from tyrosine as well as serine and threonine. In addition, PTEN is the major phosphatase for phosphoinositide-3,4,5-triphosphate, and thus down-regulates the PI3K/AKT pathway.</p>
          <p>In vitro and human immunohistochemical data suggest that PTEN traffics in and out of the nucleus [<xref ref-type="bibr" rid="phts.REF.ginnpease.2003.282">Ginn-Pease &#x00026; Eng 2003</xref>, <xref ref-type="bibr" rid="phts.REF.chung.2005.4108">Chung et al 2005</xref>, <xref ref-type="bibr" rid="phts.REF.minaguchi.2006.11677">Minaguchi et al 2006</xref>]. When PTEN is in the nucleus, it predominantly signals down the protein phosphatase and MAPK pathway to elicit cell cycle arrest [<xref ref-type="bibr" rid="phts.REF.chung.2005.8096">Chung &#x00026; Eng 2005</xref>]. One of the nuclear functions of PTEN is to stabilize the genome [<xref ref-type="bibr" rid="phts.REF.shen.2007.157">Shen et al 2007</xref>]. When in the cytoplasm, its lipid phosphatase predominantly signals down the AKT pathway to elicit apoptosis.</p>
          <p>Somatic <italic toggle="yes">PTEN</italic> variants and loss of gene expression are frequently found in both endometrioid endometrial adenocarcinoma and precancerous endometrial lesions (intraepithelial neoplasia), confirming the critical role that <italic toggle="yes">PTEN</italic> must play in endometrial tissues [<xref ref-type="bibr" rid="phts.REF.mutter.2000.924">Mutter et al 2000</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">PTEN</italic> comprises nine exons and likely spans a genomic distance of more than 120 kb. The 1209-bp coding sequence is predicted to encode a 403-amino acid protein. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="phts" object-id="phts.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> Germline pathogenic variants have been found throughout <italic toggle="yes">PTEN</italic> (with the exception of exon 9) and include missense, nonsense, and splice-site variants, small deletions, insertions, and large deletions. More than 150 unique pathogenic variants are currently listed in the Human Gene Mutation Database (see <related-object source-id="gene" document-id="phts" object-id="phts.molgen.TA">Table A</related-object>). Nearly 40% of pathogenic variants are found in exon 5, which encodes the phosphate core motif [<xref ref-type="bibr" rid="phts.REF.eng.2003.183">Eng 2003</xref>]. Most pathogenic variants are unique, although a number of recurrent pathogenic variants have been reported, particularly those in <xref ref-type="table" rid="phts.T.selected_pten_recurrent_pathogeni">Table 3</xref>.</p>
          <table-wrap id="phts.T.selected_pten_recurrent_pathogeni" position="anchor" orientation="portrait">
            <label>Table 3. </label>
            <caption>
              <p>Selected <italic toggle="yes">PTEN</italic> Recurrent Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.388C&#x0003e;T&#x000a0;<sup>1</sup><hr/></td>
                  <td headers="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg130Ter<hr/></td>
                  <td headers="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000314.4">NM_000314.4</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000305.3">NP_000305.3</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.697C&#x0003e;T&#x000a0;<sup>1</sup><hr/></td>
                  <td headers="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg233Ter<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1003C&#x0003e;T&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_phts.T.selected_pten_recurrent_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg335Ter</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="phts.TF.3.1">
                <label>1. </label>
                <p>Recurrent pathogenic variants [<xref ref-type="bibr" rid="phts.REF.bonneau.2000.109">Bonneau &#x00026; Longy 2000</xref>, <xref ref-type="bibr" rid="phts.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</xref>, <xref ref-type="bibr" rid="phts.REF.orloff.2008.5387">Orloff &#x00026; Eng 2008</xref>]</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Approximately 10% of individuals with CS who do not have a pathogenic variant detected in the <italic toggle="yes">PTEN</italic> coding sequence have heterozygous germline pathogenic variants in the <italic toggle="yes">PTEN</italic> promoter [<xref ref-type="bibr" rid="phts.REF.zhou.2003b.404">Zhou et al 2003b</xref>]. In contrast, 10% of individuals with BRRS who do not have an identifiable <italic toggle="yes">PTEN</italic> pathogenic variant on sequence analysis have large deletions within or encompassing <italic toggle="yes">PTEN</italic> [<xref ref-type="bibr" rid="phts.REF.zhou.2003b.404">Zhou et al 2003b</xref>].</p>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">PTEN</italic> encodes an almost ubiquitously expressed dual-specificity phosphatase. The PTEN protein localizes to specific nuclear and cytoplasmic components. The wild-type protein is a major lipid phosphatase that down-regulates the PI3K/Akt pathway to cause G1 cell cycle arrest and apoptosis. In addition, the protein phosphatase appears to play an important role in inhibition of cell migration and spreading, as well as down-regulating several cell cyclins [<xref ref-type="bibr" rid="phts.REF.eng.2003.183">Eng 2003</xref>]. It appears that nuclear PTEN mediates cell cycle arrest, while cytoplasmic PTEN is required for apoptosis [<xref ref-type="bibr" rid="phts.REF.chung.2005.8096">Chung &#x00026; Eng 2005</xref>].</p>
          <p><bold>Abnormal gene product.</bold> The majority (76%) of germline pathogenic variants in <italic toggle="yes">PTEN</italic> predict either truncated protein, lack of protein (haploinsufficiency), or dysfunctional protein. Many missense variants are functionally null and several act as dominant negatives [<xref ref-type="bibr" rid="phts.REF.weng.2001a.237">Weng et al 2001a</xref>, <xref ref-type="bibr" rid="phts.REF.weng.2001b.599">Weng et al 2001b</xref>]. When PTEN is absent, decreased, or dysfunctional, phosphorylation of AKT1 is uninhibited, leading to the inability to activate cell cycle arrest and/or to undergo apoptosis. In addition, through lack of protein phosphatase activity, the mitogen-activated protein kinase (MAPK) pathway is dysregulated, leading to abnormal cell survival [<xref ref-type="bibr" rid="phts.REF.eng.2003.183">Eng 2003</xref>].</p>
        </sec>
      </sec>
      <sec id="phts.References">
        <title>References</title>
        <sec id="phts.Published_GuidelinesConsensus_State">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="phts.Published_GuidelinesConsensus_State.reflist0">
            <ref id="phts.REF1">
              <mixed-citation publication-type="webpage">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jco.ascopubs.org/content/28/5/893.long">online</ext-link>; registration or institutional access required. 2010. Accessed 5-27-16.</mixed-citation>
            </ref>
            <ref id="phts.REF.eng.2000">
              <mixed-citation publication-type="webpage">Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 37:828-30. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jmg.bmj.com/content/37/11/828.long">online</ext-link>. 2000. Accessed 5-27-16.</mixed-citation>
            </ref>
            <ref id="phts.REF3">
              <mixed-citation publication-type="webpage">National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Clinical Practice Guidelines in Oncology. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp">online</ext-link> (registration required). 2015. Accessed 5-27-16.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="phts.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="phts.Literature_Cited.reflist0">
            <ref id="phts.REF.bennett.2010.2724">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.</article-title>
                <source>JAMA</source>
                <volume>304</volume>
                <fpage>2724</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">21177507</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.biesecker.1999.389">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Happle</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulliken</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weksberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>JM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Viljoen</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>MM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation.</article-title>
                <source>Am J Med Genet</source>
                <volume>84</volume>
                <fpage>389</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">10360391</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.bonneau.2000.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longy</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutations of the human PTEN gene.</article-title>
                <source>Hum Mutat</source>
                <volume>16</volume>
                <fpage>109</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">10923032</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.butler.2005.318">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Butler</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dasouki</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>XP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Talebizadeh</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>TN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miles</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratton</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pilarski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.</article-title>
                <source>J Med Genet</source>
                <volume>42</volume>
                <fpage>318</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">15805158</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.caux.2007.767">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Caux</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chibon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faivre</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fain</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vabres</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Selma</surname>
                    <given-names>ZB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laroche</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e9;rard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longy</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLEMAN) syndrome is related to mosaic PTEN nulligosity.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>15</volume>
                <fpage>767</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">17392703</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.chung.2005.8096">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis.</article-title>
                <source>Cancer Res</source>
                <volume>65</volume>
                <fpage>8096</fpage>
                <lpage>100</lpage>
                <pub-id pub-id-type="pmid">16166282</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.chung.2005.4108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginn-Pease</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein.</article-title>
                <source>Cancer Res</source>
                <volume>65</volume>
                <fpage>4108</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">15899801</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.dasouki.2001.s280">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dasouki</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishmael</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Macrocephaly, macrosomia and autistic behavior due to a de novo PTEN germline mutation.</article-title>
                <source>Am J Hum Genet Suppl</source>
                <volume>69</volume>
                <fpage>S280</fpage>
              </element-citation>
            </ref>
            <ref id="phts.REF.delnatte.2006.1066">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Delnatte</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanlaville</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mougenot</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vermeesch</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houdayer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blois</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genevieve</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulet</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryns</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaubert</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vekemans</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyonnet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romana</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoppa-Lyonnet</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes.</article-title>
                <source>Am J Hum Genet</source>
                <volume>78</volume>
                <fpage>1066</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">16685657</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.eng.2000.828">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Will the real Cowden syndrome please stand up: revised diagnostic criteria.</article-title>
                <source>J Med Genet</source>
                <volume>37</volume>
                <fpage>828</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">11073535</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.eng.2003.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>PTEN: one gene, many syndromes.</article-title>
                <source>Hum Mutat</source>
                <volume>22</volume>
                <fpage>183</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">12938083</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.fackenthal.2001.159">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fackenthal</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richardson</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cummings</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olopade</surname>
                    <given-names>OI</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Male breast cancer in Cowden syndrome patients with germline PTEN mutations.</article-title>
                <source>J Med Genet</source>
                <volume>38</volume>
                <fpage>159</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">11238682</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.ginnpease.2003.282">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ginn-Pease</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0G1 in MCF-7 cells.</article-title>
                <source>Cancer Res</source>
                <volume>63</volume>
                <fpage>282</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12543774</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.goffin.2001.521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goffin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoefsloot</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosgoed</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swillen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryns</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>PTEN mutation in a family with Cowden syndrome and autism.</article-title>
                <source>Am J Med Genet</source>
                <volume>105</volume>
                <fpage>521</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11496368</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.gorlin.1992.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gorlin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>MM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Condon</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Bannayan-Riley-Ruvalcaba syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>44</volume>
                <fpage>307</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">1336932</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.harach.1999.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harach</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soubeyran</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longy</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Thyroid pathologic findings in patients with Cowden disease.</article-title>
                <source>Ann Diagn Pathol</source>
                <volume>3</volume>
                <fpage>331</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">10594284</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.hartmann.1999.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hartmann</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaid</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crotty</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Myers</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petty</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sellers</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonnell</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frost</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenkins</surname>
                    <given-names>RB</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.</article-title>
                <source>N Engl J Med</source>
                <volume>340</volume>
                <fpage>77</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">9887158</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.heald.2010.1927">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Heald</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orloff</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.</article-title>
                <source>Gastroenterology</source>
                <volume>139</volume>
                <fpage>1927</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">20600018</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.herman.2007a.589">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herman</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butter</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enrile</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastore</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prior</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sommer</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2007a</year>
                <volume>143A</volume>
                <fpage>589</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">17286265</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.herman.2007b.268">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herman</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henninger</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratliff-Schaub</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastore</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgerald</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McBride</surname>
                    <given-names>KL</given-names>
                  </name>
                </person-group>
                <year>2007b</year>
                <article-title>Genetic testing in autism: how much is enough?</article-title>
                <source>Genet Med</source>
                <volume>9</volume>
                <fpage>268</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">17505203</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.hildenbrand.2001.362">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hildenbrand</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgdorf</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lautenschlager</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Cowden syndrome-diagnostic skin signs.</article-title>
                <source>Dermatology</source>
                <volume>202</volume>
                <fpage>362</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11455162</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.lindhurst.2011.611">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lindhurst</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sapp</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teer</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finn</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannons</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bick</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blakemore</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumhorst</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brockmann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calder</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deardorff</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Everman</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenstein</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keppler-Noreuil</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuznetsov</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamoto</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ng</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rothenberg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartzentruber</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singhal</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tirabosco</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Upton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zackai</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoag</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whitewood-Neal</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartzberg</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darling</surname>
                    <given-names>TN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosi</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mullikin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A mosaic activating mutation in <italic toggle="yes">AKT1</italic> associated with Proteus syndrome.</article-title>
                <source>N Engl J Med</source>
                <volume>365</volume>
                <fpage>611</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21793738</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.loffeld.2006.1194">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Loffeld</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLellan</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Payne</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fricker</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moss</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Epidermal naevus in Proteus syndrome showing loss of heterozygosity for an inherited PTEN mutation.</article-title>
                <source>Br J Dermatol</source>
                <volume>154</volume>
                <fpage>1194</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16704655</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.marsh.1998.507">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulon</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunetta</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocca-Serra</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liaw</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubou&#x000e9;</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richardson</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnetblanc</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressieux</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabarrot-Moreau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chompret</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demange</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eeles</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yahanda</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fearon</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fricker</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorlin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hodgson</surname>
                    <given-names>SV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LePrat</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Odent</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toulouse</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olopade</surname>
                    <given-names>OI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobol</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tishler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parsons</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peacocke</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.</article-title>
                <source>Hum Mol Genet</source>
                <volume>7</volume>
                <fpage>507</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">9467011</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.marsh.1999.1461">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kum</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunetta</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorlin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodurtha</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crowe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curtis</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dasouki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunn</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feit</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraghty</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>JM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Hodgson</surname>
                    <given-names>SV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korf</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manchester</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miesfeldt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murday</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nathanson</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parisi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pober</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolmie</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trembath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zackai</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zori</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weng</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PLM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.</article-title>
                <source>Hum Mol Genet</source>
                <volume>8</volume>
                <fpage>1461</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">10400993</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.mcgarrity.2003.1429">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McGarrity</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner Baker</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruggiero</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiboutot</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hampel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>XP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>GI polyposis and glycogenic acanthosis of the esophagus associated with PTEN mutation positive Cowden syndrome in the absence of cutaneous manifestations.</article-title>
                <source>Am J Gastroenterol</source>
                <volume>98</volume>
                <fpage>1429</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">12818292</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.mester.2012.1187.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prescott</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome.</article-title>
                <source>Urology.</source>
                <year>2012</year>
                <volume>79</volume>
                <fpage>1187.e1</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22381246</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.minaguchi.2006.11677">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minaguchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waite</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Nuclear localization of PTEN is regulated by Ca(2+) through a tyrosil phosphorylation-independent conformational modification in major vault protein.</article-title>
                <source>Cancer Res</source>
                <volume>66</volume>
                <fpage>11677</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">17178862</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.mutter.2000.924">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mutter</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgerald</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kum</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baak</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weng</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.</article-title>
                <source>J Natl Cancer Inst</source>
                <volume>92</volume>
                <fpage>924</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">10841828</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF33">
              <mixed-citation publication-type="webpage">NCCN. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Clinical Practice Guidelines in Oncology. 2015. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp">online</ext-link> (registration required). Accessed 5-27-16.</mixed-citation>
            </ref>
            <ref id="phts.REF.nelen.1999.267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nelen</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konings</surname>
                    <given-names>IB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoute</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Essen</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryns</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoefsloot</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peeters</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Padberg</surname>
                    <given-names>GW</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>7</volume>
                <fpage>267</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">10234502</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.nelen.1996.114">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nelen</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Padberg</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peeters</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Helm</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frants</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulon</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Reen</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Easton</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eeles</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hodgsen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulvihill</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murday</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucker</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariman</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Starink</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponder</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ropers</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Localization of the gene for Cowden disease to chromosome 10q22-23.</article-title>
                <source>Nat Genet</source>
                <volume>13</volume>
                <fpage>114</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8673088</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.ngeow.2011.e2063">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ngeow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ni</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2011</year>
                <volume>96</volume>
                <fpage>E2063</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">21956414</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.ni.2012.300">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ni</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moline</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orloff</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ringel</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2012</year>
                <volume>21</volume>
                <fpage>300</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">21979946</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.ni.2008.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ni</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zbuk</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadler</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patocs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lobo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edelman</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platzer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orloff</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waite</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.</article-title>
                <source>Am J Hum Genet</source>
                <volume>83</volume>
                <fpage>261</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18678321</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.orloff.2008.5387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orloff</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.</article-title>
                <source>Oncogene</source>
                <volume>27</volume>
                <fpage>5387</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">18794875</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.orloff.2013.76">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orloff</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>92</volume>
                <fpage>76</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">23246288</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.orrico.2009.195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orrico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buoni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orsi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vonella</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorrentino</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel PTEN mutations in neurodevelopmental disorders and macrocephaly.</article-title>
                <source>Clin Genet</source>
                <volume>75</volume>
                <fpage>195</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18759867</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.pritchard.2013.1004">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pritchard</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marushchak</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koehler</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raskind</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <article-title>A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing.</article-title>
                <source>Genet Med.</source>
                <year>2013</year>
                <volume>15</volume>
                <fpage>1004</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23619277</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.shen.2007.157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shen</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balajee</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pandolfi</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yin</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Essential role of PTEN in the maintenance of chromosome integrity.</article-title>
                <source>Cell</source>
                <volume>128</volume>
                <fpage>157</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">17218262</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.smith.2002.937">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirk</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theodosopoulos</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marshall</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogers</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Field</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brereton</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Germline mutation of the tumour suppressor PTEN in Proteus syndrome.</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>937</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">12471211</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.tan.2012.400">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ngeow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orloff</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Lifetime cancer risks in individuals with germline PTEN mutations.</article-title>
                <source>Clin Cancer Res.</source>
                <volume>18</volume>
                <fpage>400</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22252256</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.tan.2011.42">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rybicki</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milas</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pederson</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Remzi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orloff</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.</article-title>
                <source>Am J Hum Genet</source>
                <volume>88</volume>
                <fpage>42</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">21194675</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.varga.2009.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Varga</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastore</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prior</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herman</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McBride</surname>
                    <given-names>KL</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay and macrocephaly.</article-title>
                <source>Genet Med</source>
                <volume>11</volume>
                <fpage>111</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19265751</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.weng.2001a.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weng</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C.</given-names>
                  </name>
                </person-group>
                <article-title>PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways.</article-title>
                <source>Hum Mol Genet</source>
                <year>2001a</year>
                <volume>10</volume>
                <fpage>237</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">11159942</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.weng.2001b.599">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weng</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity in a breast cancer model.</article-title>
                <source>Hum Mol Genet</source>
                <year>2001b</year>
                <volume>10</volume>
                <fpage>599</fpage>
                <lpage>604</lpage>
                <pub-id pub-id-type="pmid">11230179</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.yehia.2015.661">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yehia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niazi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ni</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ngeow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sankunny</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mester</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keri</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Germline heterozygous variants in SEC23B are associated with Cowden syndrome and enriched in apparently sporadic thyroid cancer.</article-title>
                <source>Am J Hum Genet</source>
                <year>2015</year>
                <volume>97</volume>
                <fpage>661</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">26522472</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.zbuk.2007.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zbuk</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Cancer phenomics: RET and PTEN as illustrative models.</article-title>
                <source>Nat Rev Cancer</source>
                <volume>7</volume>
                <fpage>35</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">17167516</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.zhou.2001.210">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hampel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiele</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorlin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennekam</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parisi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes.</article-title>
                <source>Lancet</source>
                <volume>358</volume>
                <fpage>210</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">11476841</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.zhou.2000.765">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>XP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hampel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulliken</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gimm</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Germline and germline mosaic PTEN mutations associated with a Proteus- like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.</article-title>
                <source>Hum Mol Genet</source>
                <volume>9</volume>
                <fpage>765</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10749983</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.zhou.2003a.1191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>XP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsh</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaudhury</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maxwell</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reifenberger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003a</year>
                <article-title>Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults.</article-title>
                <source>Am J Hum Genet</source>
                <volume>73</volume>
                <fpage>1191</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14566704</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.zhou.2003b.404">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>XP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waite</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pilarski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hampel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bos</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dasouki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldman</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ivanovich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matloff</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patterson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierpont</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nassif</surname>
                    <given-names>NT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003b</year>
                <article-title>Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.</article-title>
                <source>Am J Hum Genet</source>
                <volume>73</volume>
                <fpage>404</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">12844284</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="phts.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="phts.Suggested_Reading.reflist0">
            <ref id="phts.REF.eng.2010.70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Mendelian genetics of rare - and not so rare - cancers.</article-title>
                <source>Ann N Y Acad Sci</source>
                <volume>1214</volume>
                <fpage>70</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">20946573</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.eng">
              <mixed-citation publication-type="webpage">Eng C, Parsons R. Cowden syndrome. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chap 45. McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>. Accessed 5-27-16.</mixed-citation>
            </ref>
            <ref id="phts.REF.epstein.2008">
              <mixed-citation publication-type="book">Epstein CJ, Erickson RP, Wynshaw-Boris A, eds. <italic toggle="yes">Inborn Errors of Development: The Molecular Basis of Clinical Disorders of Morphogenesis.</italic> Oxford, UK: Oxford University Press; 2008.</mixed-citation>
            </ref>
            <ref id="phts.REF.hobert.2009.687">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hobert</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>PTEN hamartoma tumor syndrome: an overview.</article-title>
                <source>Genet Med</source>
                <volume>11</volume>
                <fpage>687</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19668082</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.page.2009.1989">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Page</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuti</surname>
                    <given-names>OJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prestia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sur</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Haploinsufficiency for Pten and serotonin transporter cooperatively influences brain size and social behavior.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>106</volume>
                <fpage>1989</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19208814</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.sweet.2005.2465">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sweet</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>XP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallione</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alhopuro</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khoo</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patocs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bridgeman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pilarski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehtonen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prior</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teh</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.</article-title>
                <source>JAMA</source>
                <volume>294</volume>
                <fpage>2465</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">16287957</pub-id>
              </element-citation>
            </ref>
            <ref id="phts.REF.trepanier.2004.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trepanier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahrens</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKinnon</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stopfer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grumet</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Culver</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acton</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsen-Haidle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Correia</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pettersen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferlita</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costalas</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunt</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donlon</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skrzynia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callif-Daley</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>CW</given-names>
                  </name>
                  <collab>National Society of Genetic Counselors</collab>
                </person-group>
                <year>2004</year>
                <article-title>Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors.</article-title>
                <source>J Genet Couns</source>
                <volume>13</volume>
                <fpage>83</fpage>
                <lpage>114</lpage>
                <pub-id pub-id-type="pmid">15604628</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="phts.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="phts.Author_Notes">
          <title>Author Notes</title>
          <p>Dr Eng is the chair and coordinator of the International Cowden Syndrome Consortium, founding Chairwoman of the Cleveland Clinic Genomic Medicine Institute and a primary researcher in the field of PTEN-related disorders. The Cleveland Clinic Genomic Medicine Institute program features the only multi-disciplinary Cowden Syndrome center in the US, with ongoing clinical and molecular research protocols in PHTS.</p>
        </sec>
        <sec id="phts.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We are eternally grateful to the many patients and families who have participated in our research and who continue to educate us in the ever-broadening clinical spectrum of PHTS, without which this review and these management recommendations could not have been written. Our PHTS research has been continuously supported by the American Cancer Society and the Doris Duke Distinguished Clinical Scientist Award, and recently, by the National Cancer Institute. CE is the Sondra J and Stephen R Hardis Chair of Cancer Genomic Medicine at the Cleveland Clinic.</p>
        </sec>
        <sec id="phts.Author_History">
          <title>Author History</title>
          <p>Charis Eng, MD, PhD (2001-present)Heather Hampel, MS; Ohio State University (2001-2006)Robert Pilarski, MS; Ohio State University (2001-2006)Jennifer L Stein, MS, CGC; Cleveland Clinic (2006-2009)Kevin M Zbuk, MD; Cleveland Clinic (2006-2009)</p>
        </sec>
        <sec id="phts.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>2 June 2016 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>23 January 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 April 2012 (ce) Somatic <italic toggle="yes">AKT1</italic> mutations reported to result in Proteus syndrome [<xref ref-type="bibr" rid="phts.REF.lindhurst.2011.611">Lindhurst et al 2011</xref>]</p>
            </list-item>
            <list-item>
              <p>21 July 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>5 May 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>10 January 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>19 May 2004 (ce) Revision: Genetic Counseling posted to live Web site</p>
            </list-item>
            <list-item>
              <p>17 December 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>23 May 2003 (ce) Revision: Differential Diagnosis</p>
            </list-item>
            <list-item>
              <p>29 November 2001 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>10 July 2001 (ce) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="phts.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Trichilemmoma</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="phts-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="phts.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Papillomatous papules in the periocular region (A) and on the dorsum of the hand (B)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="phts-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
